Polyphyllin I reverses the resistance of osimertinib in non-small cell lung cancer cell through regulation of PI3K/Akt signaling

Polyphyllin I activates AMPK to suppress the growth of non-small-cell lung cancer via induction of autophagy

(2020) Yezi Wu et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway

(2020) Xiaozhen Liu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

(2020) Hongjing Zang et al.   Molecular Oncology

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy

(2020) Wenfeng Fang et al.   Translational Lung Cancer Research

Anticancer activity of Polyphyllin I in nasopharyngeal carcinoma by modulation of lncRNA ROR and P53 signaling

(2019) Feilong Hong et al.   JOURNAL OF DRUG TARGETING

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

(2019) Hirokazu Taniguchi et al.   Nature Communications

Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis

(2019) P. Xing et al.   Clinical & Translational Oncology

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells

(2019) Donghwa Kim et al.   Cell Death & Disease

The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens

(2019) Yi-Ying Wu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Paris Polyphylla Inhibits Colorectal Cancer Cells via Inducing Autophagy and Enhancing the Efficacy of Chemotherapeutic Drug Doxorubicin

(2019) Liang-Tzung Lin et al.   MOLECULES

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

(2019) Alessandro Leonetti et al.   BRITISH JOURNAL OF CANCER

Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion

(2019) Silvia La Monica et al.   Targeted Oncology

Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer

(2019) Fei Cao et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines

(2019) Jordi Codony-Servat et al.   Translational Lung Cancer Research

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib

(2019) Yiting Li et al.   CANCER

Polyphyllin I Induces Cell Cycle Arrest and Cell Apoptosis in Human Retinoblastoma Y-79 Cells through Targeting p53

(2018) Xue Zhu et al.   Anti-Cancer Agents in Medicinal Chemistry

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer

(2018) Hiroki Sato et al.   CANCER SCIENCE

Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis

(2018) Yunfei Zhang et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer

(2018) Qi Yang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation

(2018) Jean Bernard Auliac et al.   LUNG CANCER

Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer

(2017) Honggang Wang et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

EGFR G796D mutation mediates resistance to osimertinib

(2017) Di Zheng et al.   Oncotarget

High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression

(2016) Sai-Hong Ignatius Ou et al.   LUNG CANCER

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment

(2013) Hye-Ryoun Kim et al.   LUNG CANCER